Menu Search
Equities

Klaria Pharma Holding AB (publ)

6FN:FRA

Klaria Pharma Holding AB (publ)

Actions
  • Price (EUR)0.036
  • Today's Change-0.004 / -9.09%
  • Shares traded37.50k
  • 1 Year change+68.22%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 07:13 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Klaria Pharma Holding AB (publ) is a Sweden-based holding company engaged in the biotechnology and medical research industry. Through its group subsidiaries, the Company is active in developing and commercializing therapeutic drugs and treatment methods in the fields of migraine and pain related to cancer based on a patented drug delivery platform in the form of an alginate-based polymer film, which facilitates rapid and reliable transmucosal absorption via a muco-adhesive film. The Company operates Klaria Pharma AB as a wholly owned subsidiary.

  • Revenue in SEK (TTM)-6.53m
  • Net income in SEK-18.21m
  • Incorporated2014
  • Employees5.00
  • Location
    Klaria Pharma Holding AB (publ)Virdings Alle 2UPPSALA 754 50SwedenSWE
  • Phone+46 84464299
  • Websitehttps://www.klaria.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.